Table 3.

Phase I clinical trial targeting survivin for advanced and recurrent breast cancer (15 patients)

Survivin 2B 80-88 (AYACNTSTL) peptide vaccine alone (ten patients)
Vaccination	0.1–1.0 mg of survivin-2B peptide every 2 weeks for a total of four times
Toxicities	No adverse response
Surrogate marker response	Eight patients showed increased level of tumor markers (CEA, CA15-3, NCC-ST-439, and ICTP are examined); level decreased slightly in one patient
Immunologic response	Three patients (30%) showed increased peptide-specific CTL
Survivin 2B 80-88 (AYACNTSTL) peptide + IFA (four patients)
Vaccination	1.0 mg of survivin 2B peptide mixed with IFA every 2 weeks for a total of four times
Toxicities	Two patients had induration; one patient had general malaise (grade 1); one patient had general malaise and fever
Surrogate marker response	All patients showed increased level of tumor markers (CEA, CA15-3, NCC-ST-439, and ICTP are examined)
Immunologic response	Four patients (100%) demonstrated increased peptide-specific CTL